Genmab signs agreement with DSM Biologics  

2004.06.15
Biotech company Genmab has signed an agreement with DSM Biologics to produce clinical and commercial supplies of HuMax-CD4

Biotech company Genmab has signed an agreement with DSM Biologics to produce clinical and commercial supplies of HuMax-CD4, Genmab's antibody for the treatment of T-cell lymphoma. DSM Biologics is a business unit of the DSM Pharmaceutical Products business group based in Groningen, Holland and in Quebec, Canada. DSM Biologics will manufacture its product for clinical trials and subsequent commercial supply. The financial value of the agreement has not been disclosed.

 

Genmab is headquartered in Copenhagen and has operations in Utrecht, Holland and Princeton, New Jersey. Genmab creates and develops human antibodies for the treatment of life-threatening and debilitating diseases such as cancer and rheumatoid arthritis. The news is reported in a press release on Genmab's website.

 

Link > Genmab

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×